FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109305514> ?p ?o ?g. }

• W3109305514 abstract "Abstract Background The anti-malarial drug, amodiaquine, a commonly used, long-acting partner drug in artemisinin-based combination therapy, is metabolized to active desethyl-amodiaquine (DEAQ) by cytochrome P450 2C8 (CYP2C8). The CYP2C8 gene carries several polymorphisms including the more frequent minor alleles, CYP2C8*2 and CYP2C8*3 . These minor alleles have been associated with decreased enzymatic activity, slowing the amodiaquine biotransformation towards DEAQ. This study aimed to assess the influence of these CYP2C8 polymorphisms on the efficacy and tolerability of artesunate–amodiaquine (AS–AQ) treatment for uncomplicated Plasmodium falciparum malaria in Zanzibar. Methods Dried blood spots on filter paper were collected from 618 children enrolled in two randomized clinical trials comparing AS–AQ and artemether-lumefantrine in 2002–2005 in Zanzibar. Study participant were under five years of age with uncomplicated falciparum malaria. Human CYP2C8*2 and CYP2C8*3 genotype frequencies were determined by PCR-restriction fragment length polymorphism. Statistical associations between CYP2C8*2 and/or CYP2C8*3 allele carriers and treatment outcome or occurrence of adverse events were assessed by Fisher’s exact test. Results The allele frequencies of CYP2C8*2 and CYP2C8*3 were 17.5 % (95 % CI 15.4–19.7) and 2.7 % (95 % CI 1.8–3.7), respectively. There was no significant difference in the proportion of subjects carrying either CYP2C8*2 or CYP2C8*3 alleles amongst those with re-infections (44.1 %; 95 % CI 33.8–54.8) or those with recrudescent infections (48.3 %; 95 % CI 29.4–67.5), compared to those with an adequate clinical and parasitological response (36.7 %; 95 % CI 30.0-43.9) (P = 0.25 and P = 0.31, respectively). However, patients carrying either CYP2C8*2 or CYP2C8*3 alleles were significantly associated with an increased occurrence of non-serious adverse events, when compared with CYP2C8 *1/*1 wild type homozygotes (44.9 %; 95 % CI 36.1–54.0 vs. 28.1 %; 95 % CI 21.9–35.0, respectively; P = 0.003). Conclusions CYP2C8 genotypes did not influence treatment efficacy directly, but the tolerability to AS–AQ may be reduced in subjects carrying the CYP2C8*2 and CYP2C8*3 alleles. The importance of this non-negligible association with regard to amodiaquine-based malaria chemotherapy warrants further investigation." @default.
• W3109305514 created "2020-12-07" @default.
• W3109305514 creator A5013039780 @default.
• W3109305514 creator A5015312566 @default.
• W3109305514 creator A5046247834 @default.
• W3109305514 creator A5053546594 @default.
• W3109305514 creator A5063465178 @default.
• W3109305514 creator A5084119337 @default.
• W3109305514 date "2021-02-15" @default.
• W3109305514 modified "2023-10-16" @default.
• W3109305514 title "Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium falciparum malaria in Zanzibar" @default.
• W3109305514 cites W1539081991 @default.
• W3109305514 cites W1994921720 @default.
• W3109305514 cites W2027860481 @default.
• W3109305514 cites W2033261946 @default.
• W3109305514 cites W2036368368 @default.
• W3109305514 cites W2047025850 @default.
• W3109305514 cites W2049085240 @default.
• W3109305514 cites W2078687877 @default.
• W3109305514 cites W2079395738 @default.
• W3109305514 cites W2103439634 @default.
• W3109305514 cites W2103767500 @default.
• W3109305514 cites W2109989116 @default.
• W3109305514 cites W2113418233 @default.
• W3109305514 cites W2117941562 @default.
• W3109305514 cites W2122294990 @default.
• W3109305514 cites W2133057125 @default.
• W3109305514 cites W2159307889 @default.
• W3109305514 cites W2540748184 @default.
• W3109305514 cites W2756125767 @default.
• W3109305514 cites W2911448144 @default.
• W3109305514 cites W2944296683 @default.
• W3109305514 cites W3038495259 @default.
• W3109305514 cites W3040534285 @default.
• W3109305514 cites W3042927689 @default.
• W3109305514 doi "https://doi.org/10.1186/s12936-021-03620-6" @default.
• W3109305514 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7885591" @default.
• W3109305514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33588856" @default.
• W3109305514 hasPublicationYear "2021" @default.
• W3109305514 type Work @default.
• W3109305514 sameAs 3109305514 @default.
• W3109305514 citedByCount "4" @default.
• W3109305514 countsByYear W31093055142021 @default.
• W3109305514 countsByYear W31093055142022 @default.
• W3109305514 countsByYear W31093055142023 @default.
• W3109305514 crossrefType "journal-article" @default.
• W3109305514 hasAuthorship W3109305514A5013039780 @default.
• W3109305514 hasAuthorship W3109305514A5015312566 @default.
• W3109305514 hasAuthorship W3109305514A5046247834 @default.
• W3109305514 hasAuthorship W3109305514A5053546594 @default.
• W3109305514 hasAuthorship W3109305514A5063465178 @default.
• W3109305514 hasAuthorship W3109305514A5084119337 @default.
• W3109305514 hasBestOaLocation W31093055141 @default.
• W3109305514 hasConcept C104317684 @default.
• W3109305514 hasConcept C109650736 @default.
• W3109305514 hasConcept C115368759 @default.
• W3109305514 hasConcept C126322002 @default.
• W3109305514 hasConcept C135763542 @default.
• W3109305514 hasConcept C157410074 @default.
• W3109305514 hasConcept C197934379 @default.
• W3109305514 hasConcept C203014093 @default.
• W3109305514 hasConcept C2776120307 @default.
• W3109305514 hasConcept C2776992834 @default.
• W3109305514 hasConcept C2778048844 @default.
• W3109305514 hasConcept C2778059366 @default.
• W3109305514 hasConcept C2778371730 @default.
• W3109305514 hasConcept C2778375690 @default.
• W3109305514 hasConcept C37463918 @default.
• W3109305514 hasConcept C526171541 @default.
• W3109305514 hasConcept C54355233 @default.
• W3109305514 hasConcept C62231903 @default.
• W3109305514 hasConcept C71924100 @default.
• W3109305514 hasConcept C86803240 @default.
• W3109305514 hasConcept C98274493 @default.
• W3109305514 hasConceptScore W3109305514C104317684 @default.
• W3109305514 hasConceptScore W3109305514C109650736 @default.
• W3109305514 hasConceptScore W3109305514C115368759 @default.
• W3109305514 hasConceptScore W3109305514C126322002 @default.
• W3109305514 hasConceptScore W3109305514C135763542 @default.
• W3109305514 hasConceptScore W3109305514C157410074 @default.
• W3109305514 hasConceptScore W3109305514C197934379 @default.
• W3109305514 hasConceptScore W3109305514C203014093 @default.
• W3109305514 hasConceptScore W3109305514C2776120307 @default.
• W3109305514 hasConceptScore W3109305514C2776992834 @default.
• W3109305514 hasConceptScore W3109305514C2778048844 @default.
• W3109305514 hasConceptScore W3109305514C2778059366 @default.
• W3109305514 hasConceptScore W3109305514C2778371730 @default.
• W3109305514 hasConceptScore W3109305514C2778375690 @default.
• W3109305514 hasConceptScore W3109305514C37463918 @default.
• W3109305514 hasConceptScore W3109305514C526171541 @default.
• W3109305514 hasConceptScore W3109305514C54355233 @default.
• W3109305514 hasConceptScore W3109305514C62231903 @default.
• W3109305514 hasConceptScore W3109305514C71924100 @default.
• W3109305514 hasConceptScore W3109305514C86803240 @default.
• W3109305514 hasConceptScore W3109305514C98274493 @default.
• W3109305514 hasFunder F4320309793 @default.
• W3109305514 hasFunder F4320322315 @default.
• W3109305514 hasFunder F4320322581 @default.
• W3109305514 hasFunder F4320334779 @default.
• W3109305514 hasIssue "1" @default.

• next